Dividend confirmation

EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that the Board has confirmed a cash dividend of 1p per ordinary share which will be paid on 1 December 2020.

The dividend timetable dates are below:

Ex-dividend date:	5 November 2020
Record date:	6 November 2020
Payment date:	1 December 2020

Enquiries:

EKF Diagnostics Holdings plc Christopher Mills, Non-Executive Chairman Julian Baines, CEO Richard Evans, FD and COO	www.ekfdiagnostics.com Tel: 00 44 29 2071 0570
N+1 Singer (Nomad & Broker) Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking)	Tel: 020 7496 3000
Walbrook PR Limited Paul McManus Lianne Cawthorne	Tel: 020 7933 8780 or Mob: 07980 541 893 / 07584 391 303

Back to Listing Previous Next

EKF Diagnostics

EKF Diagnostics Holdings plc is a manufacturer and distrbutor of IVD products. It has three core divisions: Point of Care including hemoglobin and HbA1c analyzers; Central Laboratory including the manufacture of enzymes and clinical chemistry; and Molecular Diagnostics which incorporates a unique DNA enrichment technology, PointMan, and a portfolio of molecular testing services.

News & events

EKF introduces accurate quantitative COVID-19 antibody test kit

New COVID-SeroKlir SARS-CoV-2 IgG antibody test kit is one of first to detect both the presence and precise levels of COVID-19 neutralizing antibodies

EKF launches PrimeStore® MTM pathogenic sample collection and transportation kit

New sample collection kit enables convenient and safe collection, transportation and handling of pathogenic samples including COVID-19 and influenza.

PrimeStore® MTM successfully evaluated by Public Health England for SARS-CoV-2 inactivation

Patented transport media manufactured by EKF Diagnostics can help to increase COVID-19 testing capacity

What is the difference between standard Viral and Molecular Transport Media?

To support the increase in COVID-19 testing globally, a safe and easy sample collection and transport mechanism is essential. Learn how PrimeStore^® MTM, a novel viral transport media, enables safe molecular testing for multiple pathogens from one sample swab when compared to standard viral transport media.

EKF introduces novel molecular transport media for dual COVID-19 and influenza sampling

Patented PrimeStore^® MTM technology enables safe sample handling and testing for multiple pathogens from one sample swab